Inactive Instrument

Hikal Limited Stock NSE India S.E.

Equities

INE475B01014

Pharmaceuticals

End-of-day quote NSE India S.E.
- INR - Intraday chart for Hikal Limited

Financials

Sales 2024 17.85B 214M 293M Sales 2025 * 20.04B 240M 329M Capitalization 40.35B 484M 662M
Net income 2024 696M 8.34M 11.42M Net income 2025 * 1.14B 13.64M 18.67M EV / Sales 2024 1.83 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 2.01 x
P/E ratio 2024
47 x
P/E ratio 2025 *
35.4 x
Employees -
Yield 2024
0.45%
Yield 2025 *
0.28%
Free-Float 30.92%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 50 95-12-31
Founder 76 88-07-07
Director of Finance/CFO - -
Members of the board TitleAgeSince
Founder 76 88-07-07
Chief Executive Officer 50 95-12-31
Director/Board Member 72 92-02-04
More insiders
Hikal Limited is an India-based company, which is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities. The Pharmaceuticals segment produces active pharmaceutical ingredients. Its facilities are in Jigani, Bangalore and Panoli, Gujrat. The Crop protection segment produces pesticides and herbicides. Its facilities are in Taloja, Mahad, Maharashtra and Panoli, Gujarat. Its human health product categories include anti-convulsant, anti-emetic, anti-histaminic, anti-depressant, anti-psychotic, anti-lipemic, hemorheologic, anti-diabetic, anti-thrombotic, anti-viral, anti-inflammatory, analgesic and anti-parasitic. Its animal health product categories include anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone and NSAID. Its crop protection product categories include algaecide, biocide, fungicide, herbicide, insecticide and intermediate.
More about the company